USPH — U.S. Physical Therapy, Inc. stock price, charts and financials

NYSE·Healthcare·Medical - Care Facilities·USA

Latest market price

75.86

-1.95-2.51%

Overview Short InterestFilings

USPHQT37U.S. Physical Therapy, Inc.·NYSE

Overview Short InterestFilings

75.86-2.51%

Earnings

Down 2.5% — Reported earnings — EPS missed by 11%, revenue missed by 1%.

High confidence

Loading chart...

Screen all →

NUTX+3.18%$157.80 AMN+0.76%$33.25 PNTG-3.91%$38.61 INNV-3.38%$10.85 ARDT+0.00%$10.75 TALK-1.15%$5.15 AGL+0.71%$94.78 HCSG-1.11%$23.15

Snapshot

Index	-	P/E	151.72	EPS (ttm)	0.50	Insider Own	5.60%	Shs Outstand	15.22M	Perf Week	-3.97%

Market Cap	1.15B	Forward P/E	22.24	EPS next Y	3.41	Insider Trans	-0.55%	Shs Float	14.84M	Perf Month	3.38%

Enterprise Value	1.45B	PEG	11.31	EPS next Q	-	Inst Own	-	Short Float	6.84%	Perf Quarter	6.97%

Income	1.00M	P/S	1.58	EPS this Y	459.76%	Inst Trans	-	Short Ratio	4.55	Perf Half Y	-9.32%

Sales	729.00M	P/B	1.47	EPS next Y	21.89%	ROA	0.10%	Short Interest	1.02M	Perf YTD	-2.86%

Book/sh	51.45	P/C	41.23	EPS next 5Y	13.41%	ROE	0.24%	52W High	93.50 -18.87%	Perf Year	8.40%

Cash/sh	1.84	P/FCF	17.99	EPS past 3/5Y	-24.81% -19.07%	ROIC	5.49%	52W Low	58.19 30.37%	Perf 3Y	-35.06%

Dividend Est.	1.84 (2.43%)	EV/EBITDA	14.04	Sales past 3/5Y	12.20% 13.05%	Gross Margin	20.44%	Volatility	4.26% 4.28%	Perf 5Y	-36.52%

Dividend TTM	1.82 (2.40%)	EV/Sales	1.98	EPS Y/Y TTM	-72.83%	Oper. Margin	11.96%	ATR (14)	3.12	Perf 10Y	26.88%

Dividend Ex-Date	May 22, 2026	Quick Ratio	1.19	Sales Y/Y TTM	8.64%	Profit Margin	0.16%	RSI (14)	55.77	Recom	2.23

Dividend Gr. 3/5Y	3.15% 41.26%	Current Ratio	1.19	EPS Q/Q	-4.17%	SMA20	1.39%	Beta	1.10	Target Price	96.00

Payout	2318.81%	Debt/Eq	0.55	Sales Q/Q	29.41%	SMA50	9.82%	Rel Volume	0.99	Prev Close	77.81

Employees	7,294	LT Debt/Eq	0.49	Earnings	Aug 05	SMA200	-0.25%	Avg Volume	244.99K	Price	75.86

IPO Date	May 29, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.05% -1.32%	Net Debt/EBITDA	3.23	Volume	242,643	Change	-2.51%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-13-26	Reiterated	Barrington Research	Outperform	$98 → $90
Mar-09-26	Reiterated	Jefferies	Buy	$102
Feb-28-25	Reiterated	Barrington Research	Outperform	$98
Dec-16-24	Upgrade	B of A Securities	Neutral → Buy
Oct-07-24	Downgrade	B of A Securities	Buy → Neutral
Sep-19-23	Upgrade	CJS Securities	Market Perform → Market Outperform
Dec-14-21	Upgrade	CJS Securities	Market Perform → Market Outperform
May-07-21	Upgrade	Barrington Research	Market Perform → Outperform
May-03-21	Upgrade	Jefferies	Hold → Buy
Feb-26-21	Downgrade	Barrington Research	Outperform → Market Perform

Latest News

Jul-22-26

Jul-22-2607:30AM

U.S. Physical Therapy, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call Datesbusinesswire.com

Jul-16-26

Jul-16-2612:09PM

1 Profitable Stock Worth Your Attention and 2 We AvoidYahoo

Jul-02-26

Jul-02-2607:33AM

U.S. Physical Therapy Acquires Majority Stake In Twelve-Clinic Physical Therapy Practice; Financial Terms UndisclosedBenzinga

07:30AM

U.S. Physical Therapy Announces the Acquisition of a Twelve-Clinic Physical Therapy Practicebusinesswire.com

Jun-24-26

Jun-24-2609:09AM

Citizens Reiterates Market Outperform on US Physical Therapy, Maintains $98 Price TargetBenzinga

Company

U.S. Physical Therapy, Inc., through its various subsidiaries, manages a network of outpatient physical therapy facilities. These clinics deliver a range of services, including rehabilitation before and after surgery, treatment for musculoskeletal conditions, recovery from sports-related trauma, proactive health measures, assistance for workers recovering from injuries, and care for neurological conditions. The company's business is divided into two primary divisions: Physical Therapy Operations and Industrial Injury Prevention Services. Within its industrial segment, it provides specialized services like on-site injury avoidance and recovery programs, strategies for enhancing physical performance, pre-employment screening tests, assessments of an individual's work capacity, and workplace ergonomic reviews. These offerings are delivered by licensed physical therapists and expert certified athletic trainers to a diverse clientele, including Fortune 500 corporations, insurance providers, and their associated contractors. By the end of 2021, specifically December 31st, the company had established 591 operational clinics across 39 states, in addition to overseeing 35 other physical therapy sites. Established in 1990, the company maintains its headquarters in Houston, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	729	781	671	605	553	495	423	482	454
Cost of Goods Sold Incl. D&A	581	624	547	483	441	378	329	369	352
Gross Profit	150	157	124	122	112	117	94	112	102
Selling, General and Administrative Excl. Other	31	0	58	0	46	47	42	45	41
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	32	77	3	69	9	0	0	0	0
Operating Income	87	80	63	52	57	71	52	67	60
Interest Expense	9	9	8	9	6	1	2	2	2
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-7	7	5	7	5	3	15	6	2
Net Income Before Taxes	72	78	60	49	56	73	66	71	60
Income Taxes	18	20	15	12	12	15	13	14	11
Consolidated Net Income	1	15	26	15	28	28	31	28	10
Net Income From Continuing Operations	53	58	46	37	43	58	52	57	49
Net Income	1	15	26	15	28	28	31	28	10
EPS (Recurring)	0.50	1.42	1.84	1.28	3.34	4.49	4.09	4.49	0.80
EPS (Basic, Before Extraordinaries)	0.50	1.42	1.84	1.28	3.34	4.49	4.09	4.49	0.80
EPS (Diluted)	0.50	1.42	1.84	1.28	3.34	4.49	4.09	4.49	0.80
EBITDA	103	110	87	74	76	86	78	83	72
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	151.72	54.99	48.21	72.77	24.26	21.28	29.40	25.47	127.94
Price To Sales Ratio	1.56	1.50	1.98	2.16	1.90	2.51	3.70	3.08	2.93
Gross Margin	20.58	20.10	18.48	20.17	20.25	23.64	22.22	23.24	22.47
Operating Margin	11.93	10.24	9.39	8.60	10.31	14.34	12.29	13.90	13.22
Net Margin	0.14	1.92	3.87	2.48	5.06	5.66	7.33	5.81	2.20
Shares Outstanding	15	15	15	14	13	13	13	13	13
Market Capitalization	1,138	1,171	1,331	1,304	1,053	1,242	1,563	1,487	1,331
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Minan Peter Francis	Director	Jun 09 '26	Buy	61.50	288	17,712	3,211	Jun 10
Minan Peter Francis	Director	Jun 08 '26	Buy	63.14	492	31,065	2,923	Jun 10
REEVE GRAHAM D.	COO	Mar 11 '26	Sale	78.86	662	52,205	30,078	Mar 12
REEVE GRAHAM D.	COO	Mar 09 '26	Sale	78.52	1	79	0	Mar 11
REEVE GRAHAM D.	COO	Mar 06 '26	Sale	82.25	1,807	148,626	1	Mar 11
Binstein Richard	EVP Gen'l Counsel & Secretary	Mar 06 '26	Sale	81.64	3,000	244,920	24,867	Mar 09
REEVE GRAHAM D.	COO	Nov 24 '25	Sale	71.01	743	52,760	20,740	Nov 25
Gilmartin Kathleen A	Director	Nov 20 '25	Buy	69.00	4,000	276,000	24,786	Nov 24
HAM NANCY	Director	Sep 11 '25	Sale	81.71	600	49,026	1,994	Sep 11
Williams Eric Joseph	President and COO	Sep 05 '25	Sale	85.25	1,000	85,250	25,331	Sep 08
READING CHRISTOPHER J	Chairman of the Board and CEO	Sep 04 '25	Sale	83.53	2,000	167,060	114,088	Sep 05
HENDRICKSON CAREY P	Chief Financial Officer	Aug 25 '25	Sale	86.11	698	60,105	27,808	Aug 25
REEVE GRAHAM D.	COO	Aug 21 '25	Sale	84.97	763	64,832	21,483	Aug 21
REEVE GRAHAM D.	COO	Aug 11 '25	Sale	86.57	1,792	155,133	22,246	Aug 12
HAM NANCY	Director	Jun 12 '25	Sale	78.01	400	31,204	2,594	Jun 13

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.